Sanofi, Regeneron Expand Partnership in $8B Deal

The structure matters more than the headline number: the bulk of the consideration is milestone-linked, so the real commitment is the upfront cash, with the rest contingent on programs that have not yet cleared development or regulatory hurdles. The muted share reaction suggests the market read this as a pipeline top-up rather than a re-rating event. Whether the four programs advance on schedule, and how much of the milestone pool is actually triggered, is the open question.